Over 12 weeks , numerical reductions from baseline in glycosylated hemoglobin ( HbA1c ) , fasting plasma glucose , and body weight were observed with dapagliflozin ( -0.38 % , -0.39 mmol/L , and -1.58 % , respectively ) versus slight numerical increases with placebo ( 0.03 % , 0.26 mmol/L , and 0.62 % , respectively ) .